Erratum to: Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use (Drugs Ther Perspect, (2016), 32, 6, (265-75), 10.1007/s40267-016-0311-8)

摘要

10.1007/s40267-016-0311-8 Page 267, Table 1, ‘How should it be administered?’ section, ‘Restarting treatment after interruption’ subsection: the cell entry in column 2, which previously read: “EU/USA: consider administering every 4 weeks” Should read: “EU: consider administering every 4 weeks”.